Zinger Key Points
- Aldeyra says the data offers a glimpse into what may be possible for many patients who are not adequately treated.
- Aldeyra expects to initiate a Phase 1/2 trial of ADX‑246 in healthy volunteers and patients with atopic dermatitis in 1H of 2024.
- Get Wall Street's Hottest Chart Every Morning
Aldeyra Therapeutics Inc ALDX released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in patients with atopic dermatitis.
Relative to baseline, the clinical trial demonstrated statistically significant and clinically relevant improvement in investigator-assessed and patient-reported outcomes, including complete resolution of affected body surface area observed in one patient and elimination of itching reported by two patients.
EASI thresholds for 50% improvement (EASI‑50), 75% improvement (EASI-75), and 90% improvement (EASI-90) were met in four patients (50%), three patients (38%), and one patient (13%), respectively.
Statistical significance was achieved for improved body surface area; one patient (13%) achieved complete clearance of affected body surface area.
Statistical significance was achieved for improvement in IGA.
Also Read: FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study.
The IGA threshold score of 0 (clear) or 1 (almost clear) was met in one (13%) patient.
Statistical significance was achieved for improvement in patient-reported itching; the clinically relevant threshold of improvement by 4 or more points was met in three patients (38%), and two patients (25%) reported elimination of itching.
Statistical significance was achieved for improvement in patient-reported eczema severity; the clinically relevant improvement threshold by 4 or more points was met in six patients (75%).
Statistical significance was achieved for improvement in depression (HAM-D, p=0.02), and numerical improvement was observed for improvement in anxiety (BAI, p=0.1).
No patients experienced flare requiring rescue therapy.
Aldeyra expects to initiate a Phase 1/2 trial of ADX‑246 in healthy volunteers and patients with atopic dermatitis in 1H of 2024. Topline results are expected in 2H of 2024.
Price Action: ALDX shares are up 15.50% at $3.42 on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
